{Reference Type}: Journal Article
{Title}: A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
{Author}: Parrondo RD;Dutta N;LaPlant BR;Elliott J;Fernandez A;Zimmerman A;Cicco G;Han B;Heslop K;Chapin D;Sher T;Roy V;Rasheed A;Das S;Chanan-Khan AA;Paulus A;Ailawadhi S;
{Journal}: Br J Haematol
{Volume}: 204
{Issue}: 5
{Year}: 2024 May 29
{Factor}: 8.615
{DOI}: 10.1111/bjh.19320
{Abstract}: This phase II study evaluated time-limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow-up time of 25.7 months, the median progression-free survival (PFS) was 22.9 months. While the primary end-point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM.